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Ebola: A Significant Threat as an Infectious Disease
Ebola virus infection is a significant threat to humans
and animals. Its origin, the disease it causes, spread of the
disease, and the risk of bioterrorism are discussed in this
article. The Ebola virus originates from Africa, with the
risk of spreading worldwide by emigration, travelling,
and transportation of animals (1, 2, 3). It has been
predicted that global warming will ease the spread of the
Ebola virus worldwide (4). There are mainly 2 threats
from the Ebola virus. First, it causes an infection that is
often fatal for humans and animals (2, 3). Second, there
is a potential that the Ebola virus could be used as a
bioterrorism agent (5).
A general overview of Ebola disease has been
provided in the review articles by Bruce and Brysiewicz
(2002), and Colebunders and Borchert (2000). Ebola
disease is also known as hemorrhagic fever. It is a disease
with hemorrhage bleedings, and high temperature. It is
seen in humans and nonhuman primates. Nonhuman
primates include monkeys, gorillas, and chimpanzees.
The term ‘Ebola’ originates from the Ebola River in the
Democratic Republic of Congo, formerly known as Zaire.
In 1976 the first human outbreak of this virus infection
occurred in the region of the Ebola River. The Ebola
infection is a very severe one. It causes death in up to
90% of infected patients. Few patients can survive this
dangerous infection. These are similar for the affected
animals (2, 3). Therefore, Ebola infection is a significant
threat to humans and animals.
Data on outbreaks of Ebola disease were given in the
articles by Bruce and Brysiewicz (2002) and Colebunders

and Borchert (2000), and in a recent internet report (6).
Following the first event in the region of the Ebola River
several other Ebola virus outbreaks occurred in Sudan,
Gabon, Uganda, and Ivory Coast, both in animals and
humans. Later, in 1989, the Ebola virus was discovered in
Reston, Virginia, USA, in monkeys (2). The monkeys had
been imported from the Philippines, but it could not be
identified how the Ebola virus had been transported to the
Philippines. The virus caused serious illness in the monkeys.
However, it did not cause disease in humans. A recent
outbreak of the disease was reported by the Ministry of
Health of the Republic of the Congo on 24 December,
2003. They had a total of 35 human cases resulting in 29
deaths (6). Thus, many human outbreaks of the Ebola virus
have occurred to date. The virus discovered in the USA did
not affect humans. These data suggest that the Ebola virus
usually affects both humans and animals; however, there
may be events that only affect animals.
Filoviruses make up the virus family that Ebola
belongs to. Their effects in humans were studied by
Murphy (7). Dr. Murphy, a world authority on viruses,
was the first doctor to look at the Ebola virus ‘face-toface’ under the electron microscope. Therefore, the first
photograph of the Ebola virus was taken by Dr. Murphy.
In the reviews by Bruce and Brysiewicz (2002) and
Colebunders and Borchert (2000) it has been mentioned
that filoviruses are extremely harmful to humans and
animals. They cause bleeding in the body, leading to
death. Three types of Ebola viruses (Zaire, Sudan and
Reston) are more dangerous than the fourth type, called
the Marburg virus. Therefore, these 3 types of Ebola
viruses are very serious threats to humans and animals.
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Laboratory findings of the Ebola virus were given by
Bruce and Brysiewicz (2002), and Colebunders and
Borchert (2000). The microscopic structure of the Ebola
virus consists of a single strand made of RNA. It easily
duplicates to form new viruses. Direct detection of the
Ebola virus can be done using several laboratory techniques.
These include ELISA testing, polymerase chain reaction, and
virus isolation. The mature virus releases large numbers of
virions (viral particles) that can be seen on
electronmicroscopic inspection of the blood of the patients
during the acute stage of infection. These viral particles can
also be seen by biopsy or autopsy. Large amounts of the
Ebola virus are usually present in the skin. Therefore, a skin
biopsy can be used to confirm Ebola infection.
Bruce and Brysiewicz (2002), and Colebunders and
Borchert (2000) mentioned that the Ebola virus is
transmitted through contact with infected patients or
primates. During outbreaks, the virus appears to be
transmitted by close physical contact with infected
persons, their clothing, and their body fluids including
blood, vomitus, stools, saliva, and sweat. The risk of
transmission from patients to other persons or to the
hospital staff varies significantly. The chances the virus
may be transmitted from a patient to nearby persons in
the early stages of the disease is lower. The chances of
transmission increase when there has been contact with a
patient in the later stages of illness (2, 3). These data
suggest that normal persons or hospital staff who come
into contact with the patients, especially with those in the
late stage of the infection, are at great risk of becoming
infected with the Ebola virus.
Clinical findings are variable in Ebola infection (2, 3).
According to Bruce and Brysiewicz (2002), the Ebola virus
has an incubation period of 2–21 days. Colebunders and
Borchert (2002) mentioned that the incubation period is
between 4 and 10 days. The onset of Ebola begins with
symptoms that resemble a cold or influenza. Within a few
hours, the body temperature rapidly rises (fever). The
patients develop fatigue, muscle pain, and headaches. They
experience cough, difficulty in swallowing, nausea, vomiting,
and abdominal pain. They have eye problems, which is an
early clinical sign. A skin rash may appear. The general
condition of the patient deteriorates rapidly. Within 48 h,
any movement of the eyes, jaw or head causes pain. Bleeding
starts. Blood comes out from the patient’s mouth, anus, eyes
and ears. Bleeding is a definitive sign of the presence of
Ebola disease. This also shows that death is close. Therefore,
by the time the disease is diagnosed, it is too late. The
2

patient develops shock, convulsions (seizures) and coma.
Death generally occurs 6–9 weeks after the first symptoms
appear (2, 3). In summary, Ebola infection starts with mild
signs resembling a cold; therefore, it might be perceived as
an insignificant disease. In the later stages, severe bleeding
occurs, which is a definitive sign of the disease.
Several precautions are recommended for the care of
patients with Ebola disease (2). During patient care the
hospital staff gives drugs and injections to the patient for
symptomatic treatment. Symptomatic treatment means
that the drugs are given for the complaints of the patient.
Otherwise, such drugs usually do not cure the disease.
First, patients should be placed in isolated rooms. All staff
members must wash their hands during patient care
activities and after contact with blood, body fluids, and
other contaminated items. All staff members must wear
gloves. Gloves must be removed after use and before
leaving the patient’s environment, followed by immediate
hand washing. They must wear masks and eye protection
or face shields during patient care. They must wear
clothing that prevents contact with the virus during
patient care activities. Patient equipment and linen must
be appropriately cleaned, and disinfected. Disposable
items are preferred. The isolation area must be a private
room, and the door must be kept closed at all times with
strict access control (2). In summary, the Ebola virus is an
important threat to the hospital staff, and while taking
care of Ebola patients all staff should do their best to
protect themselves and others from the infection.
There are a few treatment possibilities for Ebola.
Bruce and Brysiewicz (2002) mentioned that Ebola virus
infection is among Africa’s top killer diseases, and
approximately 90% of the patients die, even with the
most sophisticated health care. The virus is highly
contagious, and no vaccination or cure is available yet (2,
3). However, Geisbert and Jahrling (2003) mentioned in
their recent article that there are efforts to develop an
efficacious vaccine against Ebola. Bruce and Brysiewicz
(2002), and Colebunders and Borchert (2000)
mentioned that treatment is only symptomatic, that is,
drugs are given for the complaints of a patient. They do
not cure the disease. Some patients (10% and more) can
survive Ebola infection. In surviving patients healing is
slow. They feel fatigue, and muscle and bone pain. Eye
infection, and hearing loss are seen. In summary, in Ebola
infection, treatment is only symptomatic. There is neither
cure nor vaccination and few patients can survive.
Therefore, the Ebola virus is a real danger.

Ç. ÜSTÜN, Ö. ÖZGÜRLER

It has been mentioned that spread of the Ebola virus
is rapid, and prevention possibilities are limited (1). Bruce
and Brysiewicz (2002), and Colebunders and Borchert
(2000) also mentioned that the spread of Ebola virus
occurs rapidly. Environmental factors are important for
the spread of the virus. These include climatic conditions,
sanitation, and socioeconomic factors. Outbreaks occur
mostly in forests during the rainy season. However, the
natural reservoir of Ebola is still unknown. Currently it is
considered that mice or shrews, and certain plants whose
reproductive cycles are directly linked to weather
patterns might account for the natural reservoir (4). On
the other hand, there is evidence that patients become
with Ebola infected through contact with an infected
animal. In the outbreaks, dead chimpanzees and gorillas
were found in the forests. People of low socioeconomic
status with limited access to health care are more likely to
be infected than the social elite. Sodhi (1996) mentioned
that prevention measures are limited. Because of
international travel and immigration, doctors should be
aware of the signs of Ebola disease. It is important that
doctors must be able to recognize a case of Ebola as soon
as possible when they meet the patient. They must have
sufficient knowledge about laboratory tests on viruses.
Doctors already have experience with adequate
preventive measures for AIDS and hepatitis. This
experience would help in Ebola cases (1). Researchers
generally agree that besides the Ebola infections
occurring in Africa the most important health threat is
spread of the virus infection worldwide by emigration,
travelling, and transportation of animals (1, 2, 3). In
summary, the Ebola virus spreads rapidly and its spread
worldwide poses an important threat to human and
animal health.
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Bioterrorism Agent
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Bioterrorism is a criminal act in which terrorists
intentionally use harmful means against human beings
(5). There are different kinds of harmful means. These
include viruses, bacteria or chemicals. The aim of
bioterrorists is to threaten the community with death or
illness. Bioterrorism not only involves humans but also
the environment including animals and plants. The threat
may come from some countries and terrorist
organizations. Some rogue countries develop bioweapon
programs, as it is relatively cheap to do so, compared to

sophisticated weapons such as nuclear ones. Fortunately,
there is a low risk of a bioterrorist attack; as it is not easy
to prepare, keep, and use bioterrorism weapons.
Generally, there is a low risk of a bioterrorism attack,
however, if an event did occur there would be severe
consequences (5).
It has been reported that there are only a limited
number of biological agents that could cause a serious
threat of widespread illness and death (5). The biological
agents most likely to be used as weapons include Bacillus
anthracis, causing anthrax; Brucella species, causing
brucellosis; Clostridium botulinium, causing botulism;
Yersinia pestis, causing plague; Francisella tularensis,
causing tularemia; Variola, causing smallpox; and finally
viral diseases such as Ebola (5).
Polesky and Bhatia (2003) claim the Ebola virus has a
potential to be used as a bioterrorism agent. Geisbert and
Jahrling (2003) claim that there is a threat that Ebola can
be used in bioterrorism, and stated that the former Soviet
Union was evaluating the Ebola virus as a weapon.
Geisbert and Jahrling (2003) also mentioned that there
has been little commercial interest in developing an Ebola
virus vaccine; however, with the heightened awareness of
bioterrorism after events surrounding September 11, the
perspectives regarding the need for a vaccine against the
Ebola virus have dramatically changed. As the Ebola virus
could be prepared as a bioterrorism weapon, a vaccine is
certainly needed.
Biological weapons could be spread in several ways,
namely by contamination of food and water supplies, and
by breathing of aerosols. Aerosols would be more
dangerous than others, as they would be more effective
in disseminating a large quantity of the harmful agent to
cause mass casualties in an area (5). The most convincing
experiment that the Ebola virus has a potential to be used
as a bioterrorism agent was performed by (Johnson et
al., 1995). They gave the Ebola virus to rhesus monkeys
by inhalation and the monkeys got the infection. They
mentioned that the demonstration of fatal aerosol
transmission of the Ebola virus in monkeys reinforces the
importance of taking appropriate precautions to prevent
its potential aerosol transmission to humans (8).This
reveals that the possibility of aerogenic infection using the
Ebola virus is an important threat
An important isssue is how bioterrorism can be be
detected. It has been stated by the South Dakota
3
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Department of Health that a possible bioterrorist attack
may be announced beforehand, or may be unannounced.
When a terrorist group or a terrorist country announce
their intent or deed beforehand, public health and law
enforcement agencies as well as primary health care
providers should be on alert. On the other hand, there
always is the risk threat that an attack with a bioterrorist
weapon can happen without any announcement from a
terrorist group or country. It has been mentioned by the
South Dakota Department of Health that when such an
unannounced event occurs it should be detected by
private health care providers, and infection control and/or
public health surveillance. In this condition, the event
would be the occurrence of an unusual disease and death
in the community. Prompt recognition and reporting is
important to prevent spread of the biological agent, and
to control the number of future victims in the community
(5). These data suggest that there is a significant risk that
the Ebola virus can be used with aerosols in bioterrorism.
Bronze and Greenfield (2003) considered the
treatment options for diseases due to potential viral
agents of bioterrorism. They have given examples of how
well-known biological agents can be treated. The drug
named cidofovir has shown significant promise in animal
models to treat smallpox and viral hemorrhagic fever.
However, the application of this drug in humans is
limited. Still there are reports of some human cases in
whom cidofovir was applied, and the results were
encouraging. Bronze and Greenfield (2003) mentioned
that there is another drug, ribavirin, which has been used

to treat some hemorrhagic fever viral infections. As is
known, Ebola infection is in the same category as
hemorrhagic fever viral infections. Although ribavirin has
the capacity to treat some hemorrhagic fever viral
infections, it has been shown that the drug does not have
any positive effect on Ebola infection. Bronze and
Greenfield (2003) also mentioned that also there are
genetic studies on the viruses that may provide valuable
information for treatment and prevention strategies.
However, currently there is no effective drug or genetic
data for the treatment or prevention of the Ebola virus.
In conclusion, the Ebola virus poses 2 important
threats to humans and animals: as an infection, and as a
bioterrorism agent. Ebola infection is very serious, and is
often fatal. Ebola infections are generally confined to
Central Africa; however, there is always a risk of
spreading to the rest of the world. Furthermore, the
Ebola virus could be used as a bioterrorism weapon.
These threats are enhanced as currently no effective
treatment is available for the virus. Therefore, people
should be aware of the threats from the Ebola virus in
order to avoid infection, and scientists should try their
best to develop a treatment and vaccination.
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